ADC

Trials studying ADC

• phase2A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancernot yet recruitingn=87
• phase1A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.recruitingn=265
• phase1First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumorsrecruitingn=180
• phase1A Study of HDM2020 in Patients With Advanced Sq-NSCLCrecruitingn=150
• phase2Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancercompletedn=20
• phase1ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumoursrecruitingn=210
• phase2Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignanciesrecruitingn=178
• —Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trialsenrolling by invitationn=178